Intelligence Feed event · Capital · 2026-09-12

    Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets

    Question

    Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets

    Direct answer

    Eli Lilly's immunology franchise generated $2.6 billion across the first six months of 2026, marking a 9% increase compared to the prior-year period. While GLP-1 diabetes and obesity treatments remain the primary driver of headline growth, immunology now represents 6.1% of overall company revenue. Core growth within the segment continues to be anchored by Taltz, with incremental contributions from newly launched assets including Ebglyss and Omvoh. Lilly has supplemented organic R&D with external M&A, completing transactions for DICE Therapeutics, Morphic Holding, and Merida to strengthen oral and biologic immunology candidates.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-revenue-reaches-2-6b-in-h1-2026-on-taltz-and-m-a-assets-51a6f8

    CAPITAL
    Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets
    Eli Lilly's immunology franchise generated $2.6 billion across the first six months of 2026, marking a 9% increase compared to the prior-year period. While GLP-1 diabetes and obesity treatments remain the primary driver of headline growth, immunology now represents 6.1% of overall company revenue. Core growth within the segment continues to be anchored by Taltz, with incremental contributions from newly launched assets including Ebglyss and Omvoh. Lilly has supplemented organic R&D with external M&A, completing transactions for DICE Therapeutics, Morphic Holding, and Merida to strengthen oral and biologic immunology candidates.
    LLYABBV
    Impact
    62
    SEP 12
    SIG
    85%
    LLYABBV
    Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets
    Eli Lilly's immunology franchise generated $2.6 billion across the first six months of 2026, marking a 9% increase compared to the prior-year period. While GLP-1 diabetes and obesity treatments remain the primary driver of headline growth, immunology now represents 6.1% of overall company revenue. Core growth within the segment continues to be anchored by Taltz, with incremental contributions from newly launched assets including Ebglyss and Omvoh. Lilly has supplemented organic R&D with external M&A, completing transactions for DICE Therapeutics, Morphic Holding, and Merida to strengthen oral and biologic immunology candidates.
    → Immunology revenue diversification beyond incretin products stabilizes LLY medium-term cash flow predictability against GLP-1 pricing and supply risks.
    Impact
    Eli Lilly's immunology franchise generated $2.6 billion across the first six months of 2026, marking a 9% increase compared to the prior-year period. While GLP-1 diabetes and obesity treatments remain the primary driver of headline growth, immunology now represents 6.1% of overall company revenue. Core growth within the segment continues to be anchored by Taltz, with incremental contributions from newly launched assets including Ebglyss and Omvoh. Lilly has supplemented organic R&D with external M&A, completing transactions for DICE Therapeutics, Morphic Holding, and Merida to strengthen oral and biologic immunology candidates.
    Affected
    LLYABBV
    Transmission
    Immunology revenue diversification beyond incretin products stabilizes LLY medium-term cash flow predictability against GLP-1 pricing and supply risks.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYbiopharma revenue diversification and multi-franchise cash flow expansionUp1-3mSource reports H1 2026 immunology revenues of $2.6B, up 9% YoY, representing 6.1% of total sales.
    ABBVimmunology market share competition in dermatology and rheumatology indicationsMixed1-3mAbbVie competes directly against Taltz, Ebglyss, and Omvoh across core immunology indications.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month